PATENT
Atty. Docket No. MSE-2609

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Corey et al.

Serial No.:

09/844,816

Group Art Unit: 1627

Filed:

April 30, 2001

Examiner: Guo, Lynd

For:

TRYPSIN SUBSTRATE AND DIAGNOSTIC DEVICE, AND METHOD -

OF USING SAME

CERTIFICATION UNDER 37 CFR 1.8(a)

I hereby certify that, on the date shown below, this correspondence, and any attachments referred to herein, are being deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 under 37 CFR 1.8(a) with sufficient postage as first class mail.

Gayle Gestick

Date

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 AND §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citations listed on the enclosed Supplemental Information Disclosure Statement (modified Form PTO-1449) may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

Legible copies of all items listed in the attached modified Form PTO-1449 accompany this information statement.

PATENT Atty. Docket No. MSE-2609

The present information disclosure statement is being filed more than three months after the filing date of the application and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final Office Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311. A fee of \$180.00 as set forth in 37 CFR § 1.17(p) is required.

The Commissioner is hereby authorized to charge the required fee of \$180.00 to Deposit Account No. 50-0781. A duplicate of this transmittal is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required under this submission, or credit any overpayment, to Deposit Account 50-0781.

This information disclosure statement under 37 CFR §1.56, §1.97 and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 USC §102 or §103.

Respectfully submitted,

By:

Elizabeth A. Levy

Attorney for Applicants

Reg. No.34,375

Date: 28 Oct 2003

BAYER HEALTHCARE LLC 63 North Street Medfield, MA 02052

Tel: (508) 359-3876 Fax: (508) 359-3885

SUPPLEMENTAL  INFORMATION DISCLOSURE  TO A THANK OF A TEMENT BY APPLICANT	Application No. Filing Date Inventor Group Art Unit Examiner Name Attorney Docket No.	09/844,816 April 30, 2001 Corey et al. 1627 Guo, Lynda T. MSE-2609
Page 1 of 1		

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number	Issue Date	Name of Patentee	Relevant Pages
		6,583,108	June 24, 2003	Tamburini et al.	Whole document
· <del>· · · ·</del>				/	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Public. Date	Name of Patentee	Relevant Pages	Translation Yes/No
						PC~
					NOV TECH	, SIVEL
				<u>.</u>	-CH CENTE	7003
						1000/2900

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Name of author (CAPITAL LETTERS), title of article (when appropriate), title of item (book, magazine, journal, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
<u> </u>		

Examiner Signature	Date Considered		
Examiner: Initial if citation is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if			
not in conformance and not considered. Include conv of this form with next communication to applicant			